X

Trial Profile

Randomized study of rituximab (Mabthera) in patients with relapsed follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Filgrastim; Melphalan
Indications Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms EBMT-LYM1

Most Recent Events

15 Jan 2021 Results published in the Bone Marrow Transplantation
05 Jun 2010 Five-year efficacy results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
21 Aug 2007 Status change from recruiting to in progress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com